Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR): A French Observational Study.

Date publication

juillet 2020

Journal

Advances in therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume

Tous les auteurs :
Delemer B, Nguyen-Tan-Hon T, Coriat R, Smith D, Schillo F, Raingeard I, Sobhani I, Etienne PL, Decoudier B, Bisot-Locard S, Santos A, Raverot G, Cadiot G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32683667

Résumé

The first long-acting release (LAR) formulation of octreotide was marketed in France in the late 1990s. An injectable formulation of Sandostatin LAR (Novartis SAS) with a new diluent has been developed to facilitate its preparation and administration and to improve its use in practice.

Mots clés

Acromegaly, Neuroendocrine tumors, Nurses, Patients, Quality of life, Satisfaction, Somatostatin LAR

Référence

Adv Ther. 2020 Jul 18;: